Metaphyseal chondrodysplasia, Rosenberg type

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1837OMIM:191420Q78.5
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Metaphyseal chondrodysplasia, Rosenberg type, is an extremely rare inherited bone disorder that affects how bones grow, particularly at the metaphyses — the wide portions near the ends of long bones where growth occurs during childhood. This condition belongs to a group of skeletal disorders called metaphyseal chondrodysplasias, which share the common feature of abnormal cartilage-to-bone development at these growth regions. Children with this condition typically show short stature and skeletal abnormalities that become apparent in early childhood. The metaphyses of the long bones appear widened and irregular on X-rays. Affected individuals may experience bowed legs, waddling gait, and joint stiffness. Intelligence is typically normal, and the condition primarily affects the skeleton. Because this is an extremely rare condition with very few reported cases in the medical literature, the full spectrum of symptoms and the best approaches to management are not completely understood. Treatment is generally supportive and symptomatic, focusing on orthopedic care to manage bone and joint problems. There is currently no cure or disease-modifying therapy available. Regular monitoring by specialists familiar with skeletal dysplasias is important to track growth and address complications as they arise.

Also known as:

Key symptoms:

Short statureBowed legsWidened or irregular ends of long bonesWaddling gaitJoint stiffnessLimb shorteningDelayed growthAbnormal bone development near growth plates

Clinical phenotype terms (15)— hover any for plain English
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Metaphyseal chondrodysplasia, Rosenberg type.

View clinical trials →

No actively recruiting trials found for Metaphyseal chondrodysplasia, Rosenberg type at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Metaphyseal chondrodysplasia, Rosenberg type community →

No specialists are currently listed for Metaphyseal chondrodysplasia, Rosenberg type.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Metaphyseal chondrodysplasia, Rosenberg type.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Metaphyseal chondrodysplasia, Rosenberg typeForum →

No community posts yet. Be the first to share your experience with Metaphyseal chondrodysplasia, Rosenberg type.

Start the conversation →

Latest news about Metaphyseal chondrodysplasia, Rosenberg type

No recent news articles for Metaphyseal chondrodysplasia, Rosenberg type.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What type of metaphyseal chondrodysplasia does my child have, and how certain is the diagnosis?,Should we pursue genetic testing, and what might it tell us?,How often should my child have X-rays and growth monitoring?,Are there orthopedic treatments that could help with leg bowing or joint problems?,What physical activities are safe, and are there any we should avoid?,What is the expected adult height for my child?,Are there any clinical studies or registries we should consider joining?

Common questions about Metaphyseal chondrodysplasia, Rosenberg type

What is Metaphyseal chondrodysplasia, Rosenberg type?

Metaphyseal chondrodysplasia, Rosenberg type, is an extremely rare inherited bone disorder that affects how bones grow, particularly at the metaphyses — the wide portions near the ends of long bones where growth occurs during childhood. This condition belongs to a group of skeletal disorders called metaphyseal chondrodysplasias, which share the common feature of abnormal cartilage-to-bone development at these growth regions. Children with this condition typically show short stature and skeletal abnormalities that become apparent in early childhood. The metaphyses of the long bones appear wide

How is Metaphyseal chondrodysplasia, Rosenberg type inherited?

Metaphyseal chondrodysplasia, Rosenberg type follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Metaphyseal chondrodysplasia, Rosenberg type typically begin?

Typical onset of Metaphyseal chondrodysplasia, Rosenberg type is childhood. Age of onset can vary across affected individuals.